22 Oct 2018 10:05
 Grant of Share Options under Share Option Scheme
Â
London: Monday, October 22, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces that on October 19, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting in 2015 (the "2015 HCML Share Option Scheme").
Â
Chi-Med granted 43,000 share options under its 2015 HCML Share Option Scheme to certain employees to subscribe for Ordinary Shares subject to the acceptance of the grantees. Details of such share options granted prescribed are as follows:
Â
Date of grant | : | October 19, 2018 Â |
Exercise price of share options granted | : | GBP46.10 per Ordinary Share  |
Number of share options granted | : | 43,000 (each share option shall entitle the holder thereof to subscribe for one Ordinary Share) Â |
Closing market price of Ordinary Shares on the date of grant  | : | GBP46.10 per Ordinary Share  |
Validity period of the share options | : | From October 19, 2018 to October 18, 2028 |
Â
Â
About Chi-Med
Â
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Â
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.
Â
Â
Forward Looking Statements
Â
This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.
Â
Â
CONTACTS
Â
Investor Enquiries | Â |
Mark Lee, Senior Vice President,Corporate Finance & Development | +852Â 2121Â 8200 |
David Dible, Citigate Dewe Rogerson | +44Â 7967Â 566Â 919 (Mobile)david.dible@citigatedewerogerson.com |
Xuan Yang, Solebury Trout | +1Â (415)Â 971Â 9412 (Mobile)xyang@troutgroup.com |
 |  |
Media Enquiries | Â |
UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson | +44Â 7973Â 611Â 888 (Mobile)anthony.carlisle@cdrconsultancy.co.uk |
Americas - Brad Miles, Solebury Trout | +1Â (917)Â 570Â 7340 (Mobile)bmiles@troutgroup.com |
Hong Kong & Asia ex-China - Joseph Chi Lo, Brunswick | +852Â 9850Â 5033 (Mobile)jlo@brunswickgroup.com |
Mainland China - Sam Shen, Edelman | +86Â 1367Â 179Â 1029 (Mobile)sam.shen@edelman.com |
 |  |
Nominated Advisor | Â |
Richard Gray / Andrew Potts, Panmure Gordon (UK) Limited | +44Â (20)Â 7886Â 2500 |
Â
Â